Learn why this royalty company believes it is the best way to play commodities and inflation. on 06/22/2021. Learn More
AGN:CSE; AGNPF:OTCQB; AGW:FSE

Algernon Pharmaceuticals Inc.

Algernon is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for its lead drug NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
AGN:CSE AGNPF:OTCQB AGW:FSE

Expert Comments:

Based on various positive preclinical and clinical studies, Algernon Pharmaceuticals is pursuing Ifenprodil as a potential treatment for pancreatic tumors.
read more >

Sam Riches, Weekend Dispensary

(5/22/21)
"Algernon Pharmaceuticals Inc. says it received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its planned Phase 1 clinical trial, which is set to begin later this year with the U.K.-based Hammersmith Medicines Research. . .Algernon believes its approach could potentially lead to a breakthrough therapy designation from the FDA, which enables priority review and can fast track the clinical trial process."

Algernon Pharmaceuticals reported that Ifenprodil was shown to reduce interleukin 6 in its Phase 2b/3 COVID-19 Study, which the company states may have positive implications for its use in its ongoing Phase 2 trial of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough.
read more >
Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure.
read more >
Have we forgotten about good Covid 19 Therapeutics? KSS MD PhD, editor-in-chief of PubBio.co, discusses three gems investors should know about.
read more >
Algernon Pharmaceuticals reported expects to release topline results from the Phase 2b portion of its multinational Phase 2b/3 COVID-19 Ifenprodil study sometime during the last week of March 2021.
read more >
Algernon Pharmaceuticals aims to begin the study as soon as it receives the drug from the manufacturer.
read more >
headshot of André Uddin

André Uddin, Research Capital Corporation

(3/1/21)
"The database of the Phase 2b part of Algernon Pharmaceuticals Inc.'s Phase 2b/3 trial with ifenprodil in COVID-19 is to be locked for analysis on March 5, 2021; final results are expected to be disclosed shortly thereafter. Results of a Phase 2a trial with ifenprodil in idiopathic pulmonary fibrosis/chronic cough are expected in Q2/21 or Q3/21 for early chronic cough data and Q4/21 for full study data."

Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol.
read more >
Algernon Pharmaceuticals entered into an agreement with Charles River Laboratories, "a recognized world leader for pre-clinical neurological studies," to conduct preclinical studies for psychedelic compound DMT in stroke patients.
read more >
This clinical program of Algernon Pharmaceuticals and upcoming catalysts regarding its in-progress COVID-19 and chronic cough trials are discussed in a Mackie Research Capital Corp. report.
read more >

André Uddin, Research Capital Corporation

(2/2/21)
"Algernon Pharmaceuticals Inc. has established a program to repurpose a psychedelic compound, DMT, for stroke. . .the company is to continue a number of preclinical studies with DMT for stroke and is looking to file an investigational new drug application with the U.S. Food and Drug Administration based on DMT's historical data of Phase 1 clinical trials and new preclinical data generated by Algernon."

Clive Maund, CliveMaund.com

(2/1/21)
"Algernon Pharmaceuticals Inc. is looking like a Buy again here as it is at the bottom of the shallow uptrend that has developed from the December low, and a stop may be placed beneath the lower rail of the channel. An additional reason for buying the company here that may lead to a bigger move is the good news out of it this morning that it is commencing clinical research with a psychedelic drug for stroke treatment."

Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2.
read more >
Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials.
read more >
Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil.
read more >

Clive Maund, CliveMaund.com

(12/28/20)
"The good news with Algernon Pharmaceuticals Inc. is that the stock has now arrived at a much stronger long-term support level in a deeply oversold state, so the least we can expect is a significant bounce from here. On Thursday there was a moderately bullish candle on strong volume with it closing well off the lows, which suggests that it may be reversing here or at least have hit bottom."

Algernon Pharmaceuticals provided additional interim data from its Phase 2b/3 Ifenprodil COVID-19 study outlining several potential primary endpoints for the Phase 3 portion of the trial.
read more >
headshot of André Uddin

André Uddin, Research Capital Corporation

(12/15/20)
"Algernon Pharmaceuticals Inc. reports interim results of a COVID-19 Phase 2b/3 trial with Ifenprodil. . .The results showed two positive early trends in high-dose ifenprodil at Day 15: (i) fewer patients required mechanical ventilation and (ii) the reduction of the NEWS score (used to monitor patient status) was quicker, which could potentially translate to a faster recovery down the road. . .We are maintaining our SPECULATIVE BUY rating and TP of $0.80/share. AGN remains a high risk high reward investment opportunity."

More Expert Comments

Experts Following This Company

Dr. KSS, Founder and Editor-in-Chief – BioPub.co
Clive Maund – CliveMaund.com
headshot of André Uddin
André Uddin – Research Capital Corporation

Company News

6/3/2021 – Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil

5/27/2021 – Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke

5/17/2021 – Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

5/12/2021 – Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study

5/11/2021 – Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

4/26/2021 – Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil

4/8/2021 – Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial

4/6/2021 – Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program

3/31/2021 – Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil

3/29/2021 – Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF

3/17/2021 – Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights
 
Advancing new drug treatments for billion dollar global disease markets.
 
Conducting multiple phase II clinical trials
 
Experienced management team & globally recognized medical advisory board
catalyst Calendar
Q2
2021
U,S, FDA End-of-Phase 2 COVID-19 Study Meeting, Q2, 2021
Q4
2021
Phase 2 trial for IPF and chronic cough data expected Q4, 2021.
Q4
2021
Phase 1 Study planned for DMT, Q4 2021